EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Nektar Therapeutics (NKTR) had EBIT Margin of -126.86% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$21.81M |
|
$-36.08M |
|
-- |
|
$21.81M |
|
$49.47M |
|
$-27.66M |
|
$-7.04M |
|
$-34.70M |
|
$-34.70M |
|
$-34.73M |
|
$-36.08M |
|
$-36.08M |
|
$-34.73M |
|
$-27.66M |
|
$-23.85M |
|
16.87M |
|
16.87M |
|
$-1.31 |
|
$-1.31 |
|
| Balance Sheet Financials | |
$266.27M |
|
$2.06M |
|
$14.14M |
|
$280.41M |
|
$53.54M |
|
-- |
|
$137.04M |
|
$190.57M |
|
$89.83M |
|
$89.83M |
|
$89.83M |
|
20.38M |
|
| Cash Flow Statement Financials | |
$-208.51M |
|
$-1.20M |
|
$180.57M |
|
$44.25M |
|
$15.12M |
|
$-29.14M |
|
$12.65M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-126.86% |
|
|
EBIT Margin |
-126.86% |
-- |
|
-159.13% |
|
-165.45% |
|
$-208.68M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
-- |
|
-- |
|
-- |
|
-40.16% |
|
-40.16% |
|
-12.87% |
|
-40.16% |
|
$4.41 |
|
$-12.37 |
|
$-12.36 |
|